Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

NCT02957656 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

NIH

Sponsor class

Conditions

Influenza A Virus, H7N9 Subtype

Interventions

BIOLOGICAL: H7N9 pLAIV
BIOLOGICAL: H7N9 pIIV
BIOLOGICAL: AS03 adjuvant

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)